Exelixis
EXEL
#2109
Rank
โ‚น632.25 B
Marketcap
โ‚น2,216
Share price
-1.53%
Change (1 day)
23.95%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total debt

Total debt on the balance sheet as of June 2024 : โ‚น16.61 B

According to Exelixis's latest financial reports the company's total debt is โ‚น16.61 B. A companyโ€™s total debt is the sum of all current and non-current debts.

Exelixis - Total debt on balance sheet (from 2000 to 2024)

Total debt by year

Year Total debt Change
2023-12-31โ‚น15.81 B0.48%
2022-12-31โ‚น15.73 B311.85%
2021-12-31โ‚น3.82 B6.62%
2020-12-31โ‚น3.58 B4.87%
2019-12-31โ‚น3.41 B229.37%
2018-12-31โ‚น1.03 B8.78%
2017-12-31โ‚น0.95 B-92.58%
2016-12-31โ‚น12.85 B-53.72%
2015-12-31โ‚น27.77 B22.93%
2014-12-31โ‚น22.59 B5.27%
2013-12-31โ‚น21.45 B16.72%
2012-12-31โ‚น18.38 B91.47%
2011-12-31โ‚น9.60 B2.75%
2010-12-31โ‚น9.34 B151.99%
2009-12-31โ‚น3.70 B-36.61%
2008-12-31โ‚น5.85 B22.09%
2007-12-31โ‚น4.79 B-11.07%
2006-12-31โ‚น5.38 B-19.56%
2005-12-31โ‚น6.69 B15.58%
2004-12-31โ‚น5.79 B14.37%
2003-12-31โ‚น5.06 B42.92%
2002-12-31โ‚น3.54 B50.13%
2001-12-31โ‚น2.36 B238.46%
2000-12-31โ‚น0.69 B20.68%
1999-12-31โ‚น0.57 B

Total debt for similar companies or competitors

Company Total debt differencediff. Country
โ‚น1.798 T 10,725.89%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น2.135 T 12,757.84%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น3.170 T 18,983.21%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น4.530 T 27,172.41%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น5.255 T 31,536.17%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น3.480 T 20,853.25%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น5.761 T 34,582.38%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น0.29 B-98.20%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น3.24 B-80.47%๐Ÿ‡บ๐Ÿ‡ธ USA